Great story from Carlos Ontiveros and Tyler Curiel on the role opf PD-L2 in anti-tumor immunity in old subjects with melanoma. PD-L1 and PD-1 blockade are often equated but biologically it is not the same and they may have different clinical applications. rdcu.be/eQWiw

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization: ir.anixa.com/press-releas...

The promise of TIL therapy for glioblastoma. Inspiring perspective from Mustafa Kharaw's team on their ongoing work to make immunotherapy effective against one of the most devastating human cancers: www.sciencedirect.com/science/arti...

Anixa Biosciences, Inc. (ANIX), which is testing CER T cells redirected against FSHR with FSH in patients with relapsed, chemoresisatnt ovarian cancer, will participate in the upcoming Water Tower Research Fireside Chat Series (November 11, 2025, at 11:00am PT) us06web.zoom.us/webinar/regi...

Leukocyte-intrinsic ER stress responses contribute to chemotherapy-induced peripheral neuropathy | Science Translational Medicine www.science.org/doi/10.1126/...

Medicine Nobel for researchers who characterized the immunobiology of regulatory T cells (previously "suppressor T cells"): www.science.org/content/arti...

working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era url: academic.oup.com/jnci/article...

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology: ir.anixa.com/press-releas...

Immune memory shapes ovarian cancer recurrence: Comment on the article of Ghisoni and Dangaj in Cancer Cell www.cell.com/cancer-cell/...

Dr. Robert Wenham, principal investigator for Anixa's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will be presenting at the 13th Annual Ovarcoming Cancer Conference, being held September 18 – 19, 2025, at the Briar Club in Houston, Texas. ir.anixa.com/press-releas...

This new study from Dangaj& Ghisoni in Cancer Cell analyzed 131 matching primary/relapsed ovarian cancers, to show that the immune landscape of the original tumor is re-established in the recurrent lesion, which depends on HRD status and pre-existing TIL:myeloid niches. www.cell.com/cancer-cell/...

Federal government freezes $108 million in NIH funding to Duke. Apparently for racial discrimination...against white Anglos in the Deep South...this sounds like a Tarantino movie... www.dukechronicle.com/article/2025...

In this new study, Aaron Ring and colleagues demonstrate the importance of antibody responses on the effectiveness of patients with cancer treated with ICI. As for treatment naive tumors, these are autoandibodies thsat in most cases do not cause autoimmunity: rdcu.be/exGyT

Improving lung cancer tumor infiltrating lymphocytes (TILs) manufacturing - Cytotherapy www.isct-cytotherapy.org/article/S146...

NIH announces end to funding for animal-only studies. This is potentially catastrophic. www.drugdiscoverytrends.com/nih-announce...

Zelig Eshhar, leading cancer researcher and immunologist, and the father of CAR T cells, dies at 84: www.timesofisrael.com/zelig-eshhar...

Great article from Tao wang in Nature Cancer: The abundance of tumor antigen-targeting antibodies is predictive of ICI response. Plus a new computational method to predict binding between antibodies and antigens that can be scaled to high-throughput sequencing data www.nature.com/articles/s43...

Building Better Immunotherapy: Using a method spearheaded by led by José Ramón Conejo-Garcia, MD, PhD, and Scott Antonia, MD, PhD (pictured here), immune cells are being engineered to find and attack cancer tumors. 🔗: medschool.duke.edu/stories/buil... #AcademicSky #MedSky #Immunobiology

Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial. No dose-limiting toxicities were observed in the third cohort. The trial is enrolling women with recurrent ovarian cancer who have progressed after two prior therapies. ir.anixa.com/press-releas...

Hear from OCRP leaders in this video series on how the Ovarian Cancer Academy supports researchers in making ovarian cancer the focus of their scientific careers and accelerating progress in the field: www.youtube.com/watch?v=rC2G... www.youtube.com/watch?v=ogO4... www.youtube.com/watch?v=DwWV...

Dr. Roger Li receives the Young Investigator Award of the Society of Urologic Oncology. I cannot imagine a more deserved prize. Congratulations, Roger! suonet.org/awards/young...

Anixa Biosciences Outlines Significant Progress and Key Milestones in Shareholder Letter#United_States#Anixa_Biosciences#San_Jose#CAR-T_therapy#Breast_Cancer_Vaccine

Excited to help show biology of TIL cell therapy resistance in lung cancer! Important findings in real world samples: >Missing neoantigens at progression >Failure of persistence of antigen-specific clones >HLA LOH www.nature.com/articles/s43...

New Global Ovarian Cancer Research Consortium Joins Forces with Microsoft’s AI for Good Lab to Launch First-Of-Its-Kind $1M Global Grant to Improve Survival Rates ocrahope.org/news/new-glo...

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology. The treatment is so far safe in all patients and effective in a subset of patients with recurrent ovarian cancer. Trial ongoing with more results coming soon. ir.anixa.com/press-releas...

What Is Actually the Point of Treating the N.I.H. Like This? www.nytimes.com/2025/04/11/o...

A working group report from the 2024 NCI/GCSC endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era: academic.oup.com/jnci/advance...

To recap, Trump officials have suspended funds to: 1. Columbia ($400 million) 2. Brown ($510 million) 3. UPenn ($175 million) 4. Harvard ($9 billion) 5. Cornell ($1 billion) Perhaps we need to form a coalition or an alliance to band together. Maybe a League of some kind?

Of HIFs and hERVs: Neoantigen generation in kidney cancer: Cancer Cell www.cell.com/cancer-cell/...

A teeny bit of information officially from NIH... nexus.od.nih.gov/all/2025/03/...

‪Please join us for our April #GDTcellClub #gdTcells webinar with talks by Drs. Maria Ciofani and Rafael Machado Rezende. April 10 @ 12pm (New York) | 5pm (London) nyulangone.zoom.us/j/9589051706... Zoom ID: 958 9051 7066 Passcode: 369081 @payalyokota.bsky.social @clairemci.bsky.social

I am dissapointed that the brighthest minds in the world did not see the assault of the Trump administration on higher education coming. The plan was there and this interview illustrates some of what is about to come: www.nytimes.com/2025/03/07/o...

White House Plans to Pause $175 Million for Penn First Columbia, then hopkins, now Penn. There is a plan... www.nytimes.com/2025/03/19/u...

‘Colossally Wasteful’: Trump’s Cuts Imperil Medical Research at Columbia www.nytimes.com/2025/03/18/n...

The prospect of an H5N1 pandemic is concerning for everyone but Kennedy. This study from Scott Hensley suggests that older individuals could be better protected than younger patients, who would benefit from vaccination. Patterns of the 1918 pandemic came to mind. www.nature.com/articles/s41...

Urge Senate to Oppose 57% Cut to Congressionally Directed Medical Research Programs in House-Passed CR www.votervoice.net/Shares/BAAAA...

The House of Representatives just passed a CR that includes devastating cuts to the Congressionally Directed Medical Research Program (CDMRP) – 57% cut. It is absolutely critical that we reach out to our Senators now and urge them NOT to include these cuts. Call them!

I have confirmation from several sources now that all T32s, many F30s and F31s, and most or all Center awards (P30, P50) have been terminated at Columbia. This is quite damaging to research and to individuals. This is pure terrorism and cannot be legal. But litigation will take time...

So much damage has been already done: "As universities face cuts to research funding, it's time for 'damage control' at Duke" abcnews.go.com/US/wireStory...

ProPublica published a list of 30 DOGE employees. While I oppose sharing their personal information, it is striking that 80% are under 40. In medicine and biomedical research, true independence typically comes that age. These young fellas simply cannot make informed decisions on these fields.

We are losing a generation of scientists: As Trump Goes After Universities, Students Are Now on the Chopping Block www.nytimes.com/2025/03/06/u...

Drafts of the Constitution were translated to other languages in 1787 to ensure that all Americans understood it. The First Amendment was not limited to one language. Now a monolingual ignorant tries to make America an English-only country. www.whitehouse.gov/presidential...

Research from Filippo Veglia published in Cancer Discovery shows how functional reprogramming of neutrophils within the brain tumor microenvironment by hypoxia-driven histone lactylation transforms them into tumor-promoting players: aacrjournals.org/cancerdiscov...

I may disagree with others but this is what I see when I analyze TLS in human ovarian cancer: oncologytube.com/immunotherap...

This study, with Fred Locke as corresponding author, shows that allogeneic CAR T cells can elicit durable complete responses against lymphoma. CART persistence>4 months. No severe CRS and no GVHD, paving the way for a new geenration of "off-the-shelf" CART ascopubs.org/doi/10.1200/...

They are now rescheduling study sections. Just heard from the SRO of a SEP that was scheduled to review my submission in March that they are pushing it back to April because of the federal register issue. Here's hoping it gets resolved by then...

Registration for the 12th Annual Southeastern Immunology Symposium in bautiful Charlottesville is now available: www.immunology.virginia.edu/sis2025/inde...

A gentle reminder that abstract submissions for the #gdTcells conference close on March 15. 👉🏼 na.eventscloud.com/website/7048...

This is a brave opinion from Harold Varmus on the ongoing slaughter of Science. Why is not everybody else puzzled about the complicit silence of industry in this mess? www.nytimes.com/2025/02/14/o...